CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $38.25, moving +1.38% from the previous trading session.

Aera Therapeutics shifts focus to lipid nanoparticles for T-cell targeting therapy while continuing work on protein ...

Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

Repare Therapeutics has entered into an out-licensing agreement with Canadian biotechnology firm DCx for discovery platforms ...

DCx will gain rights to technology, targets, and preclinical programs from Repare along with lab space and staff in Montreal.

Detailed price information for Meta Platforms Inc (META-Q) from The Globe and Mail including charting and trades.

For decades, scientists and surgeons around the world have been trying to solve the organ donor crisis. The answer could be ...

Cathie Wood’s ARK ETFs have made significant moves in the stock market on Wednesday, April 30th, 2025, with Advanced Micro ...

CRISPR Therapeutics' revenue streams currently rely heavily on grants and collaboration revenues from its partnership with Vertex Pharmaceuticals (VRTX). The collaboration has yielded Casgevy, a ...

Iovance Biotherapeutics (NASDAQ: IOVA) and CRISPR Therapeutics (NASDAQ: CRSP) are two incredibly innovative biotechs, but ...

From enabling functional cures for genetic diseases to revolutionizing agriculture and biotechnology, CRISPR is poised to reshape global industries. The next decade will witness deeper integration of ...

Vertex Pharmaceuticals is expected to outshine projections when it reports Q1 2025 earnings, with strong sales from its ...